Expanded Access to Tipifarnib
Sponsor: Kura Oncology, Inc.
ClinicalTrials ID:NCT04809233
This program offers expanded access to tipifarnib for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL) in the U.S. Eligibility is limited to these specific conditions. Tipifarnib, the investigational drug, is provided under this program. Interested parties should contact the responsible party for more information on accessing the treatment.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
To request access, use Responsible Party contact information provided in this record.
Expanded access for tipifarnib is only available in the United States.
Eligibility Criteria
Exclusion Criteria
Diagnosed with HRAS-mutant carcinomas or peripheral T Cell Lymphoma (PTCL).
Adult, ages 18+.
Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology
Get This Program In Your Inbox
You can sign up and apply your patients for this program.